Ambio Life Sciences is thrilled to announce the launch of a study led by our co-founder, Jonathan Dickinson. This research, titled "Tracking Ibogaine Therapy Outcomes (TITO)", aims to dive into how ibogaine, a naturally occurring psychedelic with potential healing properties, can impact outcomes on addiction and mental health issues.

This includes some outcomes not often part of other studies, such prescription medication withdrawal, as use of alcohol, pornography and social media.

The Purpose of the Study

1. To understand how understudied conditions affect outcomes in ibogaine therapy.
2. To identify factors that may influence outcomes from ibogaine therapy.

‍

‍

A Closer Look at Ibogaine and Healing

Ibogaine sees increased interest by scientists and therapists alike with its unique potential to facilitate profound healing experiences and changes in well-being or behaviour. Despite its potential, the pathways through which ibogaine exerts its effects remain largely uncharted. The IRB-approved TITO study aims to fill this knowledge gap by tracking and analyzing the outcomes of ibogaine therapy.

Looking Ahead To Timelines and Expectations

Over the next two years, the TITO study will monitor how ibogaine therapy impacts participants. We anticipate the inclusion of 200 people, whose experiences will be closely followed for 6 months after their treatments. Throughout the study participants will be asked to complete questionnaires using an online portal.

Tracking Ibogaine Therapy Outcomes Study Eligibility Requirements

• Must be enrolled in Ambio Life Science’s ibogaine therapy program in Mexico
• Not detoxing from opioids, benzodiazepines, or any illicit stimulants at the time of admission
• Aged between 21 and 64 years
• Resident of the United States or Canada
• Fluent in both spoken and written English
• Must provide signed informed consent by the subject
• Must have access to a valid personal email account and a device with internet access to complete questionnaires

As we navigate through this process, we will share our progress and insights, fostering an open dialogue with our community and stakeholders.

‍

Use of the Ibogaine Therapy Study Data

We expect to publish our findings in scientific journals, contributing valuable insights to the field of psychedelic-assisted therapy. The research may also be presented at conferences or in other academic related endeavors.

Our hope is that this study will not only illuminate the therapeutic potential of ibogaine but also pave the way for future research and treatment modalities.

‍

Follow Along

Jonathan Dickinson and Ambio Life Sciences are committed to filling in the gaps in existing research in understudied areas. We anticipate the results will help to inform patient expectations and to assist in future research questions.

Do you want to enroll in the study and help us to forward the scientific understanding of how ibogaine works?

Learn more and sign up here to contribute to a growing body of research on this important matter.